PrimeVigilance looks forward to attending the upcomingย European Pharmacovigilance Congress 2024ย that will take place Online between 18-19 November and Face-to-Face in Milan on 22 November.

As leaders in the field of pharmacovigilance, regulatory affairs, and quality assurance, the team will actively engage with attendees, sharing insights on the latest industry developments and fostering discussions on quality, compliance, and best practices in the rapidly evolving regulatory landscape.

 

PrimeVigilance Expert Sessions

๐—œ๐—ก๐—ง๐—˜๐—ฅ๐—”๐—–๐—ง๐—œ๐—ฉ๐—˜ ๐—™๐Ÿฎ๐—™ ๐—ช๐—ข๐—ฅ๐—ž๐—ฆ๐—›๐—ข๐—ฃ: 22 November | 11.10-12:30 | Milan

Speaker:
Mercedina del Papa
Strategic Advisor II

Topic I: โ€œ๐—ง๐—ต๐—ฒ ๐—Ÿ๐—ฎ๐˜๐—ฒ๐˜€๐˜ ๐—ฟ๐—ฒ๐˜ƒ๐—ถ๐˜€๐—ถ๐—ผ๐—ป๐˜€ ๐—ผ๐—ณ ๐—š๐—ฉ๐—ฃ ๐—ด๐˜‚๐—ถ๐—ฑ๐—ฒ๐—น๐—ถ๐—ป๐—ฒ๐˜€ ๐—ผ๐—ป ๐—ฅ๐—ถ๐˜€๐—ธ ๐— ๐—ถ๐—ป๐—ถ๐—บ๐—ถ๐˜€๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐— ๐—ฒ๐—ฎ๐˜€๐˜‚๐—ฟ๐—ฒ๐˜€ ๐—ฎ๐—ป๐—ฑ ๐——๐—ฒ๐—ณ๐—ถ๐—ป๐—ถ๐˜๐—ถ๐—ผ๐—ป โ€“ ๐—น๐—ฒ๐˜โœ๐˜€ ๐—ป๐—ฎ๐˜ƒ๐—ถ๐—ด๐—ฎ๐˜๐—ฒ ๐˜๐—ผ๐—ด๐—ฒ๐˜๐—ต๐—ฒ๐—ฟ ๐˜๐—ต๐—ฟ๐—ผ๐˜‚๐—ด๐—ต ๐˜๐—ต๐—ฒ ๐˜‚๐—ฝ๐—ฑ๐—ฎ๐˜๐—ฒ๐˜€โ€

This webinar will focus on the recent revision of GVP Module XVI, which impacts Marketing Authorisation Holders and Applicants. A review of the role of risk minimisation in risk management planning, the effect on the risk-benefit balance of medicinal products, and the importance of evaluating the effectiveness of risk minimization measures.

Speaker:
Natalia Kocankova
Senior Strategic Advisor

Topic II: โ€œ๐—ฃ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—ฏ๐—ฒ๐˜๐˜„๐—ฒ๐—ฒ๐—ป ๐— ๐—” ๐—ฎ๐—ฝ๐—ฝ๐—น๐—ถ๐—ฐ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ฎ๐—ป๐—ฑ ๐—ฎ๐—ฝ๐—ฝ๐—ฟ๐—ผ๐˜ƒ๐—ฎ๐—น โ€“ ๐—ฐ๐—ต๐—ฎ๐—น๐—น๐—ฒ๐—ป๐—ด๐—ฒ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐˜€๐—ฝ๐—ผ๐—ป๐˜€๐—ผ๐—ฟ๐˜€ ๐˜๐—ฟ๐—ฎ๐—ป๐˜€๐—ณ๐—ผ๐—ฟ๐—บ๐—ถ๐—ป๐—ด ๐˜๐—ผ ๐— ๐—”๐—›โ€

This webinar will navigate your pharmacovigilance steps on the road mapย between Marketing application andย Marketing Approval from the MAH perspective focusing onย Pharmacovigilance system compliance and availability of the products for patients before the EU approval.

Dr. Hrvoje Maฤek
Vice President, Medical Scientific Affairs

Chair Person for session โ€œRisk Minimization Measuresโ€ย | 18 November | 3:40-5:15PM | Online

 

 

Meet our Experts

Noelle Humphrey
Vice President, Quality

Meera Sivasundram
Vice President, Business Development, Pharmacovigilance Strategy

Alessandro Di Ranno
Vice President, Business Development

Olivija Sileike
Director, Business Development

Jan Mueller
Director, Business Development

Rada Gantly
Director, Business Development

Elena ฤeriฤ‡
Global Marketing Project Management Lead

 

 

We look forward to seeing you there!